Zealand Pharma A/S/DKr ZEAL
08:00
10:00
12:00
13:55
15:55
1D1W1MYTD1Y5YMAX
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company focuses on developing treatments for gastrointestinal and metabolic diseases, including obesity and diabetes. Its product portfolio includes innovative solutions like dasiglucagon, intended for severe hypoglycemia. Founded in 1998, Zealand Pharma leverages proprietary peptide platforms to address unmet medical needs. The company's strategic positioning involves strong partnerships and collaborations with pharmaceutical companies to advance its products through various stages of clinical development.
Ticker
DKr ZEAL
Sector
Primary listing
CSE
Employees
440
Headquarters
Søborg, Denmark
Website
ZEAL Metrics
BasicAdvanced
kr 36B
5.59
kr 91.63
0.54
-
Price and volume
Market cap
kr 36B
Beta
0.54
52-week high
kr 802.50
52-week low
kr 310.00
Average daily volume
442K
Financial strength
Current ratio
14.103
Quick ratio
14.103
Long term debt to equity
2.532
Total debt to equity
2.681
Interest coverage (TTM)
233.70%
Profitability
EBITDA (TTM)
7,081.191
Gross margin (TTM)
99.99%
Net profit margin (TTM)
71.47%
Operating margin (TTM)
77.23%
Effective tax rate (TTM)
8.05%
Revenue per employee (TTM)
kr 20,810,000
Management effectiveness
Return on assets (TTM)
33.44%
Return on equity (TTM)
54.42%
Valuation
Price to earnings (TTM)
5.585
Price to revenue (TTM)
3.947
Price to book
2.37
Price to tangible book (TTM)
2.38
Price to free cash flow (TTM)
4.901
Free cash flow yield (TTM)
20.40%
Free cash flow per share (TTM)
104.426
Growth
Revenue change (TTM)
11,809.72%
Earnings per share change (TTM)
-651.45%
3-year revenue growth (CAGR)
360.92%
10-year revenue growth (CAGR)
79.16%
3-year earnings per share growth (CAGR)
52.64%
10-year earnings per share growth (CAGR)
23.92%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zealand Pharma A/S stock?
Zealand Pharma A/S (ZEAL) has a market cap of DKr36B as of December 12, 2025.
What is the P/E ratio for Zealand Pharma A/S stock?
The price to earnings (P/E) ratio for Zealand Pharma A/S (ZEAL) stock is 5.59 as of December 12, 2025.
Does Zealand Pharma A/S stock pay dividends?
No, Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders as of December 12, 2025.
When is the next Zealand Pharma A/S dividend payment date?
Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders.
What is the beta indicator for Zealand Pharma A/S?
Zealand Pharma A/S (ZEAL) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.